ClinicalTrials.gg
CompletedNCT01562275Updated Mar 28, 2016Results posted

A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Participants With Locally Advanced or Metastatic Solid Tumors

A Phase 1 interventional study of Ipatasertib and Cobimetinib in Neoplasms, sponsored by Genentech, Inc.. Completed at 5 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-03-28.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
67
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This open-label, multicenter, Phase Ib dose-escalation study will evaluate the safety, tolerability and pharmacokinetics of oral dosing of GDC-0973 and GDC-0068 administered in combination in patients with locally advanced or metastatic solid tumors. Cohorts of patients will receive multiple ascending doses of GDC-0973 and GDC-0068. Anticipated time on study treatment is until disease progression or unacceptable toxicity occurs.

02

Conditions studied

  • Neoplasms

Browse trials for

Keywords

  • GDC0973
  • MEK
  • MEK inhibitor
  • GDC0068
  • Akt
  • Akt inhibitor
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 67 is above the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.

Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.

First submitted after Genentech, Inc. became part of Hoffmann-La Roche.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically documented locally advanced or solid tumors for which standard therapies either do not exist or have proven ineffective or intolerable
  • Evaluable disease or disease measurable per (RECIST)
  • >/= 12 weeks
  • Adequate hematologic and end organ function

Exclusion criteria

Exclusion Criteria:

  • History of prior significant toxicity from another MEK pathway inhibitor requiring discontinuation of treatment
  • History of prior significant toxicity from another phosphoinositide 3-kinase (PI3K) or Akt pathway or mammalian target of rapamycin (mTOR) inhibitor requiring discontinuation of treatment
  • Anti-cancer therapy within 28 days prior to first dose of study drug, except as stated in protocol
  • History of type I or type II diabetes mellitus requiring insulin
  • Current severe, uncontrolled systemic disease (e.g. cardiovascular, pulmonary, or metabolic disease)
  • Clinically significant history of liver disease, current alcohol abuse, or current known active infection with , or virus
  • Active disease
  • Pregnant or lactating women
  • Known that are untreated, symptomatic, or require therapy to control symptoms
  • History of glaucoma
  • History of retinal vein occlusion
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
67 participants (actual)

Study arms

  • Experimental
    Dose escalation stage 1 (Arm A): Cobimetinib and Ipatasertib

    Participants will receive cobimetinib (GDC-0973) capsules (at a starting dose of 40 mg) and ipatasertib (GDC-0068) capsules (at a starting dose of 200 mg) from Days 1 to 21 and then 7 days off study drugs from Days 22 to 28 in continuous 28-day cycles. Doses will be increased to identify maximum tolerated dose (MTD) or potential recommended Phase 2 dose (RP2D). Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets.

    Drug: Ipatasertib · Drug: Cobimetinib

  • Experimental
    Dose escalation stage 1 (Arm B): Cobimetinib and Ipatasertib

    Participants will receive cobimetinib (GDC-0973) capsules (at a starting dose of 100 mg) on Days 1, 4, 8, 11, 15, and 18 and ipatasertib (GDC-0068) capsules (at a starting dose of 200 mg) from Days 1 to 21 and then 7 days off study drugs from Days 22 to 28 in continuous 28-day cycles. Doses will be increased to identify MTD or potential RP2D. Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets.

    Drug: Ipatasertib · Drug: Cobimetinib

  • Experimental
    Stage 2 (Indication specific dose expansion cohort)

    Participants will receive cobimetinib (GDC-0973) capsules on Days 1, 4, 8, 11, 15, and 18 and ipatasertib (GDC-0068) capsules from Days 1 to 21 and then 7 days off study drugs from Days 22 to 28 in continuous 28-day cycles, at doses identified as MTD/potential RP2D from Stage 1. Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets. This indication specific cohort will include participants with phosphatase and tensin homolog (PTEN)-loss triple-negative breast cancer and PTEN-loss endometrial carcinoma.

    Drug: Ipatasertib · Drug: Cobimetinib

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose Limiting Toxicities (DLTs)

    DLT is defined as 1 of the following toxicities considered by the investigator to be possibly related to study drugs: a) Grade (G) ≥3 febrile neutropenia, b) G ≥4 neutropenia (absolute neutrophil count \[ANC\] \<500/ microliter \[μL\]) lasting \>5 days , c) G ≥4 thrombocytopenia lasting \>2 days, d) G ≥4 anemia, e) G ≥3 elevation of total bilirubin or hepatic transaminase or alkaline phosphatase (ALP) lasting \>3 days, f) Hepatic transaminases \>3 × Upper Limit of Normal (ULN) and an increase in total bilirubin \>2 × ULN without any findings of cholestasis and in the absence of other contributory factors, g) G ≥2 visual changes that do not resolve to baseline within 14 days, h) 1 episode of fasting G 4 hyperglycemia or 3 episodes of fasting, i) G 3 hyperglycemia on separate days within 7 days, j) G ≥4 fasting hypercholesterolemia or triglyceridemia for ≥2 weeks, k) G ≥3 nausea, vomiting, or diarrhea despite maximal supportive medications lasting for ≥3 days.

    Time frame: Cycle 1 (28 Days)

  2. Number of DLTs Categorized as Per the Nature

    DLT is defined as 1 of the following toxicities considered by the investigator to be possibly related to study drugs: a) G ≥3 febrile neutropenia, b) G ≥4 neutropenia (ANC \<500/μL) lasting \>5 days , c) G ≥4 thrombocytopenia lasting \>2 days, d) G ≥4 anemia, e) G ≥3 elevation of total bilirubin or hepatic transaminase or ALP lasting \>3 days, f) Hepatic transaminases \>3 × ULN and an increase in total bilirubin \>2 × ULN without any findings of cholestasis and in the absence of other contributory factors, g) G ≥2 visual changes that do not resolve to baseline within 14 days, h) 1 episode of fasting G 4 hyperglycemia or 3 episodes of fasting, i) G 3 hyperglycemia on separate days within 7 days, j) G ≥4 fasting hypercholesterolemia or triglyceridemia for ≥2 weeks, k) G ≥3 nausea, vomiting, or diarrhea despite maximal supportive medications lasting for ≥3 days. Hematologic, Hepatic and non-hematologic and non-hepatic DLT categories were to be reported.

    Time frame: Cycle 1 (28 Days)

  3. Maximum Tolerated Doses (MTDs) in Combination of Cobimetinib and Ipatasertib During Dose-Escalation Stage 1

    An adverse event (AE) is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an investigational medicinal product (IMP) or other protocol-imposed intervention, regardless of attribution. On the basis of AEs that did not meet protocol-defined DLT criteria (defined in Outcome measure 1) but indicated intolerability of a given dose combination, the combination MTDs were determined (as per investigator) during Stage 1 of the study.

    Time frame: Cycle 1 (28 Days)

  4. Number of Participants With At Least One AE Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version (V) 4.0

    AE was defined in Outcome Measure 3. AEs were graded as per NCI CTCAE V 4.0 as follows: G 1: asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; G 2: minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental activities of daily living (ADL) (instrumental ADL refers to preparing meals, shopping for groceries or clothes, using the telephone, managing money and others); G 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated, disabling, limiting self care ADL (refers to bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not bedridden); G 4: Life-threatening consequences, urgent intervention indicated; G 5: Death related to AE. If a participant had multiple events of different grades, the highest grade that occurred in that participant was counted.

    Time frame: From Baseline up to 30 days after the last dose of study treatment or until initiation of another anticancer treatment whichever occurred first (Up to 33 months)

Secondary outcomes

  1. Area Under Concentration-Time Curve From Time Zero to Last Measurable Concentration After Dose [AUC0-Last] of Ipatasertib and Cobimetinib on Day 1 and Day 15

    Time frame: Predose (0 hour), 1, 2, 4, 6 and 24 hours postdose on Day 1 and Day 15 of Cycle 1

  2. Maximum Plasma Concentration (Cmax) of Ipatasertib and Cobimetinib on Day 1 and Day 15

    Time frame: Predose (0 hour), 1, 2, 4, 6 and 24 hours postdose on Day 1 and Day 15 of Cycle 1

  3. Time Taken to Reach Cmax (Tmax) of Ipatasertib and Cobimetinib on Day 1 and Day 15

    Time frame: Predose (0 hour), 1, 2, 4, 6 and 24 hours postdose on Day 1 and Day 15 of Cycle 1

  4. Last Measurable Concentration (Clast) of Ipatasertib and Cobimetinib on Day 1 and Day 15

    Time frame: Predose (0 hour), 1, 2, 4, 6 and 24 hours postdose on Day 1 and Day 15 of Cycle 1

  5. Number of Participants With Objective Response of Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)

    RECIST v1.1 (for measurable disease), CR: disappearance of all target lesions, reduction in short axis \<10 millimeters in pathological lymph nodes (target and non-target lesions); PR: at least a 30 percent (%) decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter. Responses were confirmed by repeat assessments ≥4 weeks after initial documentation.

    Time frame: Screening, Days 21-28 of Cycle 2, Day 25 (± 3 days) of Cycle 4 and every 8 weeks thereafter till study completion (Up to 33 months)

  6. Duration of Objective Response for Participants With Measurable Disease According to RECIST v1.1

    Duration of response, defined as the time from first occurrence of a documented objective response until the time of disease progression, as determined by investigator review of tumor assessments using RECIST 1.1, or death from any cause during the study (i.e., within 30 days after the last dose of study treatment).

    Time frame: Screening, Days 21-28 of Cycle 2, Day 25 (± 3 days) of Cycle 4 and every 8 weeks thereafter till study completion (Up to 33 months)

  7. Progression-Free Survival (PFS) Time for Participants With Measurable Disease According to RECIST v1.1

    PFS is defined as the time from study treatment initiation to the first occurrence of disease progression, as determined by investigator review of tumor assessments using RECIST 1.1, or death from any cause during the study (i.e., within 30 days after the last dose of study treatment).

    Time frame: Screening, Days 21-28 of Cycle 2, Day 25 (± 3 days) of Cycle 4 and every 8 weeks thereafter till study completion (Up to 33 months)

07

Results

Posted Mar 28, 2016
Limitations and caveats
As per changes in the planned analysis, PFS and duration of response outcome measures were not analyzed as only few participants experienced a measurable response.

Participant flow

Stage 1
Participant flow — Stage 1
MilestoneDEC Arm A: 40 mg Cobimetinib + 200 mg IpatasertibDEC Arm A: 60 mg Cobimetinib + 200 mg IpatasertibDEC Arm A: 60 mg Cobimetinib + 300 mg IpatasertibDEC Arm A: 40 mg Cobimetinib + 400 mg IpatasertibDEC Arm B: 100 mg Cobimetinib + 200 mg IpatasertibDEC Arm B: 125 mg Cobimetinib + 200 mg IpatasertibDEC Arm B: 125 mg Cobimetinib + 400 mg IpatasertibDEC Arm B: 150 mg Cobimetinib + 300 mg IpatasertibDEC Arm B: 175 mg Cobimetinib + 200 mg IpatasertibDEC Arm B: 150 mg Cobimetinib + 200 mg IpatasertibDEC Arm B: 100 mg Cobimetinib + 400 mg IpatasertibEndometrial Carcinoma: 140 mg Cobimetinib + 300 mg IpatasertibBreast Cancer: 140 mg Cobimetinib + 300 mg Ipatasertib
Started3734443737300
Completed0000000000000
Not completed3734443737300
Withdrew: Adverse event0001100001000
Withdrew: Death1000000000000
Withdrew: Non compliance0010000000000
Withdrew: Physician decision0000101010000
Withdrew: Progression of disease2621241725300
Withdrew: Withdrawal by subject0102001001000
Stage 2
Participant flow — Stage 2
MilestoneDEC Arm A: 40 mg Cobimetinib + 200 mg IpatasertibDEC Arm A: 60 mg Cobimetinib + 200 mg IpatasertibDEC Arm A: 60 mg Cobimetinib + 300 mg IpatasertibDEC Arm A: 40 mg Cobimetinib + 400 mg IpatasertibDEC Arm B: 100 mg Cobimetinib + 200 mg IpatasertibDEC Arm B: 125 mg Cobimetinib + 200 mg IpatasertibDEC Arm B: 125 mg Cobimetinib + 400 mg IpatasertibDEC Arm B: 150 mg Cobimetinib + 300 mg IpatasertibDEC Arm B: 175 mg Cobimetinib + 200 mg IpatasertibDEC Arm B: 150 mg Cobimetinib + 200 mg IpatasertibDEC Arm B: 100 mg Cobimetinib + 400 mg IpatasertibEndometrial Carcinoma: 140 mg Cobimetinib + 300 mg IpatasertibBreast Cancer: 140 mg Cobimetinib + 300 mg Ipatasertib
Started00000000000145
Completed0000000000000
Not completed00000000000145
Withdrew: Death0000000000021
Withdrew: Progression of disease00000000000124

Outcome measures

PrimaryNumber of Participants With Dose Limiting Toxicities (DLTs)

DLT is defined as 1 of the following toxicities considered by the investigator to be possibly related to study drugs: a) Grade (G) ≥3 febrile neutropenia, b) G ≥4 neutropenia (absolute neutrophil count \[ANC\] \<500/ microliter \[μL\]) lasting \>5 days , c) G ≥4 thrombocytopenia lasting \>2 days, d) G ≥4 anemia, e) G ≥3 elevation of total bilirubin or hepatic transaminase or alkaline phosphatase (ALP) lasting \>3 days, f) Hepatic transaminases \>3 × Upper Limit of Normal (ULN) and an increase in total bilirubin \>2 × ULN without any findings of cholestasis and in the absence of other contributory factors, g) G ≥2 visual changes that do not resolve to baseline within 14 days, h) 1 episode of fasting G 4 hyperglycemia or 3 episodes of fasting, i) G 3 hyperglycemia on separate days within 7 days, j) G ≥4 fasting hypercholesterolemia or triglyceridemia for ≥2 weeks, k) G ≥3 nausea, vomiting, or diarrhea despite maximal supportive medications lasting for ≥3 days.

Time frame:
Cycle 1 (28 Days)
Reported as:
Number · participants
Number of Participants With Dose Limiting Toxicities (DLTs)
participantsDEC Arm A: 40 mg Cobimetinib + 200 mg IpatasertibDEC Arm A: 60 mg Cobimetinib + 200 mg IpatasertibDEC Arm A: 60 mg Cobimetinib + 300 mg IpatasertibDEC Arm A: 40 mg Cobimetinib + 400 mg IpatasertibDEC Arm B: 100 mg Cobimetinib + 200 mg IpatasertibDEC Arm B: 125 mg Cobimetinib + 200 mg IpatasertibDEC Arm B: 125 mg Cobimetinib + 400 mg IpatasertibDEC Arm B: 150 mg Cobimetinib + 300 mg IpatasertibDEC Arm B: 175 mg Cobimetinib + 200 mg IpatasertibDEC Arm B: 150 mg Cobimetinib + 200 mg IpatasertibDEC Arm B: 100 mg Cobimetinib + 400 mg Ipatasertib
Number of Participants With Dose Limiting Toxicities (DLTs)00000000000
PrimaryNumber of DLTs Categorized as Per the Nature

DLT is defined as 1 of the following toxicities considered by the investigator to be possibly related to study drugs: a) G ≥3 febrile neutropenia, b) G ≥4 neutropenia (ANC \<500/μL) lasting \>5 days , c) G ≥4 thrombocytopenia lasting \>2 days, d) G ≥4 anemia, e) G ≥3 elevation of total bilirubin or hepatic transaminase or ALP lasting \>3 days, f) Hepatic transaminases \>3 × ULN and an increase in total bilirubin \>2 × ULN without any findings of cholestasis and in the absence of other contributory factors, g) G ≥2 visual changes that do not resolve to baseline within 14 days, h) 1 episode of fasting G 4 hyperglycemia or 3 episodes of fasting, i) G 3 hyperglycemia on separate days within 7 days, j) G ≥4 fasting hypercholesterolemia or triglyceridemia for ≥2 weeks, k) G ≥3 nausea, vomiting, or diarrhea despite maximal supportive medications lasting for ≥3 days. Hematologic, Hepatic and non-hematologic and non-hepatic DLT categories were to be reported.

Time frame:
Cycle 1 (28 Days)

No measurements were reported for this outcome.

PrimaryMaximum Tolerated Doses (MTDs) in Combination of Cobimetinib and Ipatasertib During Dose-Escalation Stage 1

An adverse event (AE) is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an investigational medicinal product (IMP) or other protocol-imposed intervention, regardless of attribution. On the basis of AEs that did not meet protocol-defined DLT criteria (defined in Outcome measure 1) but indicated intolerability of a given dose combination, the combination MTDs were determined (as per investigator) during Stage 1 of the study.

Time frame:
Cycle 1 (28 Days)
Reported as:
Number · milligrams
Maximum Tolerated Doses (MTDs) in Combination of Cobimetinib and Ipatasertib During Dose-Escalation Stage 1
milligramsStage 1 DECs
Arm A Cobimetinib dose60
Arm A Ipatasertib dose200
Arm B Cobimetinib dose150
Arm B Ipatasertib dose300
PrimaryNumber of Participants With At Least One AE Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version (V) 4.0

AE was defined in Outcome Measure 3. AEs were graded as per NCI CTCAE V 4.0 as follows: G 1: asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; G 2: minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental activities of daily living (ADL) (instrumental ADL refers to preparing meals, shopping for groceries or clothes, using the telephone, managing money and others); G 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated, disabling, limiting self care ADL (refers to bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not bedridden); G 4: Life-threatening consequences, urgent intervention indicated; G 5: Death related to AE. If a participant had multiple events of different grades, the highest grade that occurred in that participant was counted.

Time frame:
From Baseline up to 30 days after the last dose of study treatment or until initiation of another anticancer treatment whichever occurred first (Up to 33 months)
Reported as:
Number · participants
Number of Participants With At Least One AE Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version (V) 4.0
participantsDECs and Expansion Cohorts
Grade 1 (G 1)4
Grade 2 (G 2)15
Grade 3 (G 3)36
Grade 4 (G 4)1
Grade 5 (G 5)10
SecondaryArea Under Concentration-Time Curve From Time Zero to Last Measurable Concentration After Dose [AUC0-Last] of Ipatasertib and Cobimetinib on Day 1 and Day 15
Time frame:
Predose (0 hour), 1, 2, 4, 6 and 24 hours postdose on Day 1 and Day 15 of Cycle 1
Reported as:
Geometric mean · nanograms*hours/milliliter (ng*h/mL)
Area Under Concentration-Time Curve From Time Zero to Last Measurable Concentration After Dose [AUC0-Last] of Ipatasertib and Cobimetinib on Day 1 and Day 15
nanograms*hours/milliliter (ng*h/mL)DEC Arm A: 40 mg Cobimetinib + 200 mg IpatasertibDEC Arm A: 60 mg Cobimetinib + 200 mg IpatasertibDEC Arm A: 60 mg Cobimetinib + 300 mg IpatasertibDEC Arm A: 40 mg Cobimetinib + 400 mg IpatasertibDEC Arm B: 100 mg Cobimetinib + 200 mg IpatasertibDEC Arm B: 125 mg Cobimetinib + 200 mg IpatasertibDEC Arm B: 125 mg Cobimetinib + 400 mg IpatasertibDEC Arm B: 150 mg Cobimetinib + 300 mg IpatasertibDEC Arm B: 175 mg Cobimetinib + 200 mg IpatasertibDEC Arm B: 150 mg Cobimetinib + 200 mg IpatasertibDEC Arm B: 100 mg Cobimetinib + 400 mg IpatasertibEndometrial Carcinoma: 140 mg Cobimetinib + 300 mg IpatasertibBreast Cancer: 140 mg Cobimetinib + 300 mg Ipatasertib
Ipatasertib Day 1 (n=3,7,1,4,4,4,3,5,2,6,2,14,5)688 ± 106538 ± 33.81760 ± NA2170 ± 74.9255 ± 203956 ± 43.51420 ± 46.4790 ± 78.8838 ± 239424 ± 67.92030 ± 46.41450 ± 48.71540 ± 11.3
Ipatasertib Day 15 (n=3,6,2,1,4,3,1,6,2,5,2,7,2)703 ± 40.8781 ± 20.72440 ± 45.21750 ± NA599 ± 1331760 ± 62.32230 ± NA1260 ± 85.2668 ± 148866 ± 58.13390 ± 9.701070 ± 65.21270 ± 13.3
Cobimetinib Day 1 (n=3,7,1,4,4,4,3,5,2,6,2,14,5)1500 ± 3201130 ± 68.65050 ± NA1920 ± 87.83740 ± 1395580 ± 54.42690 ± 50.72710 ± 60.713600 ± 1113270 ± 89.24330 ± 39.311400 ± 64.110800 ± 41.0
Cobimetinib Day 15 (n=3,6,2,1,4,3,1,6,1,5,2,7,2)3250 ± 2233260 ± 48.67080 ± 91.12500 ± NA3230 ± 96.88140 ± 5.654400 ± NA4970 ± 65.58570 ± NA3980 ± 1116830 ± 38.48880 ± 64.81480 ± 10800
SecondaryMaximum Plasma Concentration (Cmax) of Ipatasertib and Cobimetinib on Day 1 and Day 15
Time frame:
Predose (0 hour), 1, 2, 4, 6 and 24 hours postdose on Day 1 and Day 15 of Cycle 1
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
Maximum Plasma Concentration (Cmax) of Ipatasertib and Cobimetinib on Day 1 and Day 15
nanograms per milliliter (ng/mL)DEC Arm A: 40 mg Cobimetinib + 200 mg IpatasertibDEC Arm A: 60 mg Cobimetinib + 200 mg IpatasertibDEC Arm A: 60 mg Cobimetinib + 300 mg IpatasertibDEC Arm A: 40 mg Cobimetinib + 400 mg IpatasertibDEC Arm B: 100 mg Cobimetinib + 200 mg IpatasertibDEC Arm B: 125 mg Cobimetinib + 200 mg IpatasertibDEC Arm B: 125 mg Cobimetinib + 400 mg IpatasertibDEC Arm B: 150 mg Cobimetinib + 300 mg IpatasertibDEC Arm B: 175 mg Cobimetinib + 200 mg IpatasertibDEC Arm B: 150 mg Cobimetinib + 200 mg IpatasertibDEC Arm B: 100 mg Cobimetinib + 400 mg IpatasertibEndometrial Carcinoma: 140 mg Cobimetinib + 300 mg IpatasertibBreast Cancer: 140 mg Cobimetinib + 300 mg Ipatasertib
Ipatasertib Day 1 (n=3,7,1,4,4,4,3,5,2,6,2,14,5)137 ± 24497.1 ± 92.2300 ± NA336 ± 11842.9 ± 560156 ± 32.8329 ± 104141 ± 34.399.9 ± 25495.8 ± 57.1262 ± 122268 ± 48.3374 ± 48.2
Ipatasertib Day 15 (n=3,6,2,1,4,3,1,6,2,5,2,7,2)94.5 ± 55.0130 ± 47.1386 ± 58.4137 ± NA86.9 ± 237165 ± 33.9441 ± NA170 ± 64.472.9 ± 200114 ± 53.9450 ± 16.9149 ± 113156 ± 12.7
Cobimetinib Day 1 (n=3,7,1,4,4,4,3,5,2,6,2,14,5)134 ± 33378.6 ± 73.2312 ± NA109 ± 85.4259 ± 192405 ± 45.9192 ± 50.3220 ± 64.91040 ± 151262 ± 59.9249 ± 46.0799 ± 55.8840 ± 56.6
Cobimetinib Day 15 (n=3,6,2,1,4,3,1,6,1,5,2,7,2)222 ± 182215 ± 61.4407 ± 72.6121 ± NA217 ± 135511 ± 14.6376 ± NA320 ± 64.5481 ± NA253 ± 103420 ± 41.4704 ± 75.284.2 ± 7940
SecondaryTime Taken to Reach Cmax (Tmax) of Ipatasertib and Cobimetinib on Day 1 and Day 15
Time frame:
Predose (0 hour), 1, 2, 4, 6 and 24 hours postdose on Day 1 and Day 15 of Cycle 1
Reported as:
Median · hours
Time Taken to Reach Cmax (Tmax) of Ipatasertib and Cobimetinib on Day 1 and Day 15
hoursDEC Arm A: 40 mg Cobimetinib + 200 mg IpatasertibDEC Arm A: 60 mg Cobimetinib + 200 mg IpatasertibDEC Arm A: 60 mg Cobimetinib + 300 mg IpatasertibDEC Arm A: 40 mg Cobimetinib + 400 mg IpatasertibDEC Arm B: 100 mg Cobimetinib + 200 mg IpatasertibDEC Arm B: 125 mg Cobimetinib + 200 mg IpatasertibDEC Arm B: 125 mg Cobimetinib + 400 mg IpatasertibDEC Arm B: 150 mg Cobimetinib + 300 mg IpatasertibDEC Arm B: 175 mg Cobimetinib + 200 mg IpatasertibDEC Arm B: 150 mg Cobimetinib + 200 mg IpatasertibDEC Arm B: 100 mg Cobimetinib + 400 mg IpatasertibEndometrial Carcinoma: 140 mg Cobimetinib + 300 mg IpatasertibBreast Cancer: 140 mg Cobimetinib + 300 mg Ipatasertib
Ipatasertib Day 1 (n=3,7,1,4,4,4,3,5,2,6,2,14,5)1.03 (1.00 to 1.05)1.02 (0.92 to 4.08)1.00 (NA to NA)1.04 (1.00 to 4.08)1.00 (0.92 to 4.78)3.04 (1.00 to 4.13)1.00 (0.90 to 2.40)2.00 (1.92 to 4.00)3.17 (2.08 to 4.25)1.08 (1.00 to 2.00)1.52 (1.00 to 2.03)1.47 (0.95 to 4.00)1.00 (1.00 to 1.00)
Ipatasertib Day 15 (n=3,6,2,1,4,3,1,6,2,5,2,7,2)2.03 (0.95 to 2.25)1.03 (1.00 to 3.83)1.04 (1.00 to 1.08)6.05 (NA to NA)1.04 (1.00 to 1.15)1.00 (1.00 to 2.00)1.00 (NA to NA)1.19 (1.00 to 6.00)1.57 (1.00 to 2.13)1.00 (0.92 to 4.08)0.98 (0.93 to 1.02)1.08 (0.92 to 3.58)0.97 (0.93 to 1.00)
Cobimetinib Day 1 (n=3,7,1,4,4,4,3,5,2,6,2,14,5)2.00 (2.00 to 4.00)3.97 (1.92 to 24.0)2.05 (NA to NA)3.83 (2.02 to 5.95)3.04 (2.00 to 6.00)3.03 (2.00 to 6.00)4.05 (4.00 to 4.27)4.00 (2.00 to 23.9)24.0 (22.0 to 26.0)3.91 (2.00 to 4.25)5.92 (5.83 to 6.00)3.08 (1.00 to 24.4)2.08 (2.00 to 5.42)
Cobimetinib Day 15 (n=3,6,2,1,4,3,1,6,1,5,2,7,2)2.25 (2.00 to 4.00)3.92 (2.08 to 4.00)3.01 (2.00 to 4.02)6.05 (NA to NA)4.78 (1.15 to 5.97)4.03 (4.00 to 24.2)1.88 (NA to NA)4.06 (2.25 to 23.7)5.92 (NA to NA)4.00 (0.00 to 5.58)13.1 (2.00 to 24.1)2.00 (1.00 to 24.3)1.96 (1.92 to 2.00)
SecondaryLast Measurable Concentration (Clast) of Ipatasertib and Cobimetinib on Day 1 and Day 15
Time frame:
Predose (0 hour), 1, 2, 4, 6 and 24 hours postdose on Day 1 and Day 15 of Cycle 1
Reported as:
Mean · ng/mL
Last Measurable Concentration (Clast) of Ipatasertib and Cobimetinib on Day 1 and Day 15
ng/mLDEC Arm A: 40 mg Cobimetinib + 200 mg IpatasertibDEC Arm A: 60 mg Cobimetinib + 200 mg IpatasertibDEC Arm A: 60 mg Cobimetinib + 300 mg IpatasertibDEC Arm A: 40 mg Cobimetinib + 400 mg IpatasertibDEC Arm B: 100 mg Cobimetinib + 200 mg IpatasertibDEC Arm B: 125 mg Cobimetinib + 200 mg IpatasertibDEC Arm B: 125 mg Cobimetinib + 400 mg IpatasertibDEC Arm B: 150 mg Cobimetinib + 300 mg IpatasertibDEC Arm B: 175 mg Cobimetinib + 200 mg IpatasertibDEC Arm B: 150 mg Cobimetinib + 200 mg IpatasertibDEC Arm B: 100 mg Cobimetinib + 400 mg IpatasertibEndometrial Carcinoma: 140 mg Cobimetinib + 300 mg IpatasertibBreast Cancer: 140 mg Cobimetinib + 300 mg Ipatasertib
Ipatasertib Day 1 (n=3,7,1,4,4,4,3,5,2,6,2,14,5)6.18 ± 4.906.07 ± 1.9923.7 ± NA25.1 ± 11.34.32 ± 2.6013.4 ± 8.2915.2 ± 5.157.05 ± 11.6018.2 ± 16.26.00 ± 4.1830.0 ± 5.6618.0 ± 10.115.4 ± 6.38
Ipatasertib Day 15 (n=3,6,2,1,4,3,1,6,2,5,2,7,2)14.1 ± 4.5411.6 ± 1.7938.0 ± 14.530.6 ± NA12.8 ± 6.8530.6 ± 22.239.3 ± NA21.90 ± 45.5013.0 ± 7.6616.9 ± 10.954.7 ± 15.520.7 ± 12.114.5 ± 8.68
Cobimetinib Day 1 (n=3,7,1,4,4,4,3,5,2,6,2,14,5)79.4 ± 11935.9 ± 10.5150 ± NA71.9 ± 44.0122 ± 76.5204 ± 17272.6 ± 30.7145 ± 1591280 ± 1120125 ± 127160 ± 17.7386 ± 237268 ± 146
Cobimetinib Day 15 (n=3,6,2,1,4,3,1,6,1,5,2,7,2)228 ± 319105 ± 58.3251 ± 19293.8 ± NA123 ± 70.2294 ± 158127 ± NA186 ± 116283 ± NA204 ± 254280 ± 53.0299 ± 172227 ± 316
SecondaryNumber of Participants With Objective Response of Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)

RECIST v1.1 (for measurable disease), CR: disappearance of all target lesions, reduction in short axis \<10 millimeters in pathological lymph nodes (target and non-target lesions); PR: at least a 30 percent (%) decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter. Responses were confirmed by repeat assessments ≥4 weeks after initial documentation.

Time frame:
Screening, Days 21-28 of Cycle 2, Day 25 (± 3 days) of Cycle 4 and every 8 weeks thereafter till study completion (Up to 33 months)
Reported as:
Number · participants
Number of Participants With Objective Response of Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)
participantsDEC Arm A: 40 mg Cobimetinib + 200 mg IpatasertibDEC Arm A: 60 mg Cobimetinib + 200 mg IpatasertibDEC Arm A: 60 mg Cobimetinib + 300 mg IpatasertibDEC Arm A: 40 mg Cobimetinib + 400 mg IpatasertibDEC Arm B: 100 mg Cobimetinib + 200 mg IpatasertibDEC Arm B: 125 mg Cobimetinib + 200 mg IpatasertibDEC Arm B: 125 mg Cobimetinib + 400 mg IpatasertibDEC Arm B: 150 mg Cobimetinib + 300 mg IpatasertibDEC Arm B: 175 mg Cobimetinib + 200 mg IpatasertibDEC Arm B: 150 mg Cobimetinib + 200 mg IpatasertibDEC Arm B: 100 mg Cobimetinib + 400 mg IpatasertibEndometrial Carcinoma: 140 mg Cobimetinib + 300 mg IpatasertibBreast Cancer: 140 mg Cobimetinib + 300 mg Ipatasertib
Number of Participants With Objective Response of Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)0001100010000
SecondaryDuration of Objective Response for Participants With Measurable Disease According to RECIST v1.1

Duration of response, defined as the time from first occurrence of a documented objective response until the time of disease progression, as determined by investigator review of tumor assessments using RECIST 1.1, or death from any cause during the study (i.e., within 30 days after the last dose of study treatment).

Time frame:
Screening, Days 21-28 of Cycle 2, Day 25 (± 3 days) of Cycle 4 and every 8 weeks thereafter till study completion (Up to 33 months)

No measurements were reported for this outcome.

SecondaryProgression-Free Survival (PFS) Time for Participants With Measurable Disease According to RECIST v1.1

PFS is defined as the time from study treatment initiation to the first occurrence of disease progression, as determined by investigator review of tumor assessments using RECIST 1.1, or death from any cause during the study (i.e., within 30 days after the last dose of study treatment).

Time frame:
Screening, Days 21-28 of Cycle 2, Day 25 (± 3 days) of Cycle 4 and every 8 weeks thereafter till study completion (Up to 33 months)

No measurements were reported for this outcome.

Adverse events

Collected over From Baseline up to 30 days after the last dose of study treatment or until initiation of another anticancer treatment whichever occurred first (Up to 33 months). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DEC Arm A: 40 mg Cobimetinib + 200 mg Ipatasertib—1/3 (33.3%)3/3 (100%)
DEC Arm A: 60 mg Cobimetinib + 200 mg Ipatasertib—2/7 (28.6%)7/7 (100%)
DEC Arm A: 60 mg Cobimetinib + 300 mg Ipatasertib—0/3 (0%)3/3 (100%)
DEC Arm A: 40 mg Cobimetinib + 400 mg Ipatasertib—2/4 (50%)4/4 (100%)
DEC Arm B: 100 mg Cobimetinib + 200 mg Ipatasertib—1/4 (25%)4/4 (100%)
DEC Arm B: 125 mg Cobimetinib + 200 mg Ipatasertib—3/4 (75%)4/4 (100%)
DEC Arm B: 125 mg Cobimetinib + 400 mg Ipatasertib—1/3 (33.3%)3/3 (100%)
DEC Arm B: 150 mg Cobimetinib + 300 mg Ipatasertib—1/7 (14.3%)7/7 (100%)
DEC Arm B: 175 mg Cobimetinib + 200 mg Ipatasertib—0/3 (0%)3/3 (100%)
DEC Arm B: 150 mg Cobimetinib + 200 mg Ipatasertib—2/6 (33.3%)6/6 (100%)
DEC Arm B: 100 mg Cobimetinib + 400 mg Ipatasertib—2/3 (66.7%)3/3 (100%)
Endometrial Carcinoma: 140 mg Cobimetinib + 300 mg Ipatasertib—10/14 (71.4%)14/14 (100%)
Breast Cancer: 140 mg Cobimetinib + 300 mg Ipatasertib—2/5 (40%)5/5 (100%)
Most frequent serious events
Showing 10 of 39
Most frequent serious events
EventDEC Arm A: 40 mg Cobimetinib + 200 mg IpatasertibDEC Arm A: 60 mg Cobimetinib + 200 mg IpatasertibDEC Arm A: 60 mg Cobimetinib + 300 mg IpatasertibDEC Arm A: 40 mg Cobimetinib + 400 mg IpatasertibDEC Arm B: 100 mg Cobimetinib + 200 mg IpatasertibDEC Arm B: 125 mg Cobimetinib + 200 mg IpatasertibDEC Arm B: 125 mg Cobimetinib + 400 mg IpatasertibDEC Arm B: 150 mg Cobimetinib + 300 mg IpatasertibDEC Arm B: 175 mg Cobimetinib + 200 mg IpatasertibDEC Arm B: 150 mg Cobimetinib + 200 mg IpatasertibDEC Arm B: 100 mg Cobimetinib + 400 mg IpatasertibEndometrial Carcinoma: 140 mg Cobimetinib + 300 mg IpatasertibBreast Cancer: 140 mg Cobimetinib + 300 mg Ipatasertib
Abdominal PainGastrointestinal disorders0/30/70/30/40/40/40/30/70/30/61/30/140/5
Gastrointestinal HaemorrhageGastrointestinal disorders0/30/70/30/40/40/41/30/70/30/60/30/140/5
Intestinal ObstructionGastrointestinal disorders1/30/70/30/40/40/40/30/70/30/60/30/140/5
Bile Duct ObstructionHepatobiliary disorders0/31/70/30/40/40/40/30/70/30/61/30/140/5
Hip FractureInjury, poisoning and procedural complications0/30/70/30/40/40/40/30/70/30/61/30/140/5
DehydrationMetabolism and nutrition disorders0/30/70/31/40/40/40/30/70/30/61/32/140/5
HyperkalaemiaMetabolism and nutrition disorders0/30/70/30/40/40/41/30/70/30/60/30/140/5
Mental Status ChangesPsychiatric disorders0/30/70/30/40/40/40/30/70/30/61/30/140/5
Renal Failure AcuteRenal and urinary disorders0/30/70/31/41/40/41/30/70/30/60/31/140/5
Atrial FibrillationCardiac disorders0/30/70/30/41/40/40/30/70/30/60/30/140/5
Most frequent other events
Showing 10 of 252
Most frequent other events
EventDEC Arm A: 40 mg Cobimetinib + 200 mg IpatasertibDEC Arm A: 60 mg Cobimetinib + 200 mg IpatasertibDEC Arm A: 60 mg Cobimetinib + 300 mg IpatasertibDEC Arm A: 40 mg Cobimetinib + 400 mg IpatasertibDEC Arm B: 100 mg Cobimetinib + 200 mg IpatasertibDEC Arm B: 125 mg Cobimetinib + 200 mg IpatasertibDEC Arm B: 125 mg Cobimetinib + 400 mg IpatasertibDEC Arm B: 150 mg Cobimetinib + 300 mg IpatasertibDEC Arm B: 175 mg Cobimetinib + 200 mg IpatasertibDEC Arm B: 150 mg Cobimetinib + 200 mg IpatasertibDEC Arm B: 100 mg Cobimetinib + 400 mg IpatasertibEndometrial Carcinoma: 140 mg Cobimetinib + 300 mg IpatasertibBreast Cancer: 140 mg Cobimetinib + 300 mg Ipatasertib
DiarrhoeaGastrointestinal disorders3/36/73/34/44/43/43/37/73/34/63/314/145/5
NauseaGastrointestinal disorders2/34/72/34/43/42/41/34/71/36/63/311/144/5
VomitingGastrointestinal disorders2/34/72/34/43/43/42/33/72/35/63/312/143/5
FatigueGeneral disorders3/33/71/32/42/41/42/34/71/34/63/35/141/5
Decreased AppetiteMetabolism and nutrition disorders1/34/70/31/42/42/40/30/71/31/63/37/141/5
Dermatitis AcneiformSkin and subcutaneous tissue disorders0/32/72/31/41/42/41/37/73/35/61/38/142/5
AstheniaGeneral disorders0/30/70/31/41/42/40/30/70/30/60/34/144/5
AnaemiaBlood and lymphatic system disorders1/34/71/31/43/43/40/30/71/31/62/36/141/5
Oedema PeripheralGeneral disorders2/32/70/32/43/42/40/32/70/31/60/31/141/5
HyponatraemiaMetabolism and nutrition disorders0/30/70/30/41/43/40/30/71/30/60/33/140/5

Baseline characteristics

All enrolled participants.

Age, Continuous
Age, Continuous(years)DEC Arm A: 40 mg Cobimetinib + 200 mg IpatasertibDEC Arm A: 60 mg Cobimetinib + 200 mg IpatasertibDEC Arm A: 60 mg Cobimetinib + 300 mg IpatasertibDEC Arm A: 40 mg Cobimetinib + 400 mg IpatasertibDEC Arm B: 100 mg Cobimetinib + 200 mg IpatasertibDEC Arm B: 125 mg Cobimetinib + 200 mg IpatasertibDEC Arm B: 125 mg Cobimetinib + 400 mg IpatasertibDEC Arm B: 150 mg Cobimetinib + 300 mg IpatasertibDEC Arm B: 175 mg Cobimetinib + 200 mg IpatasertibDEC Arm B: 150 mg Cobimetinib + 200 mg IpatasertibDEC Arm B: 100 mg Cobimetinib + 400 mg IpatasertibEndometrial Carcinoma: 140 mg Cobimetinib + 300 mg IpatasertibBreast Cancer: 140 mg Cobimetinib + 300 mg IpatasertibTotal
Mean61.0 ± 3.559.1 ± 8.758.3 ± 5.566.8 ± 16.562.3 ± 7.051.8 ± 10.959.0 ± 9.258.6 ± 11.961.0 ± 13.757.6 ± 10.952.7 ± 24.962.9 ± 8.749.0 ± 10.159.0 ± 11.0
Sex: Female, Male
Sex: Female, Male(Participants)DEC Arm A: 40 mg Cobimetinib + 200 mg IpatasertibDEC Arm A: 60 mg Cobimetinib + 200 mg IpatasertibDEC Arm A: 60 mg Cobimetinib + 300 mg IpatasertibDEC Arm A: 40 mg Cobimetinib + 400 mg IpatasertibDEC Arm B: 100 mg Cobimetinib + 200 mg IpatasertibDEC Arm B: 125 mg Cobimetinib + 200 mg IpatasertibDEC Arm B: 125 mg Cobimetinib + 400 mg IpatasertibDEC Arm B: 150 mg Cobimetinib + 300 mg IpatasertibDEC Arm B: 175 mg Cobimetinib + 200 mg IpatasertibDEC Arm B: 150 mg Cobimetinib + 200 mg IpatasertibDEC Arm B: 100 mg Cobimetinib + 400 mg IpatasertibEndometrial Carcinoma: 140 mg Cobimetinib + 300 mg IpatasertibBreast Cancer: 140 mg Cobimetinib + 300 mg IpatasertibTotal
Female2413342324114548
Male132110141320019
08

Study locations

5 sites
  • Boston, Massachusetts 02215, United States
  • Detroit, Michigan 48201, United States
  • Nashville, Tennessee 37203, United States
  • Barcelona, 08035, Spain
  • Valencia, 46010, Spain
09

References and documents

Publications

  • Shapiro GI, LoRusso P, Cho DC, Musib L, Yan Y, Wongchenko M, Chang I, Patel P, Chan IT, Sanabria-Bohorquez S, Meng RD, Bendell JC. A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors. Invest New Drugs. 2021 Feb;39(1):163-174. doi: 10.1007/s10637-020-00975-6. Epub 2020 Jul 31. PubMed 32737717 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2012, a primary completion of Jan 2015 and a completion of Jan 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2016, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2012
First posted
Mar 23, 2012
Start
Apr 2012
Primary completionActual
Jan 2015
CompletionActual
Jan 2015
Results first posted
Mar 28, 2016
Last update
Mar 28, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 28, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01562275
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Mar 23, 2012
Start date
Apr 2012
Primary completion
Jan 2015
Completion
Jan 2015
Results posted
Mar 28, 2016
Last update
Mar 28, 2016

Study contacts

Clinical Trials
study director · Genentech, Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ipatasertib · Cobimetinib

Start the discussion